Valuing Genzyme: A Health Care Reform Premium
This article was originally published in RPM Report
Executive Summary
Sanofi has gone public with an $18.5 billion bid for Genzyme, but investors assume the French company is willing to go higher. So the question everyone is asking is, How much is Genzyme worth? The answer should include a premium for the special treatment the company will get under the health care reform law in the US.
You may also be interested in...
Rare Disease Research: Where Compassion Meets Commerce
The advent of a new set of potential acquirers has heightened venture capital's interest in rare diseases, resulting in the creation of a new cohort of drug developers that are using cutting edge technologies to treat and in some cases cure grave illnesses. In this issue, we profile Afraxis, bluebird bio, Edimer Pharmaceuticals and Ultragenyx Pharmaceutical.
Price Controls in Action: Understanding the Rise of the 340B Program
The health care reform law dramatically expanded the number of entities eligible to purchase drugs via the federally administered 340B program, while simultaneously increasing the size of the mandatory discounts given to covered entities. Manufacturers are understandably frustrated. Rather than hope for elimination of the program, however, they may be better served working within the system to contain its impact.
Job One for Big Pharma: Repositioning in DC Post-Health Care Reform
How Wall Street’s reaction to the impact of health care reform may help the pharmaceutical industry make sure it pays off in the long run.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: